PLUS1
2.83
0.02 (0.71%)
0.02 (0.71%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc | BCRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.115 | -3.93% | 2.81 | 2.74 | 2.99 | 2.95 | 2.925 | 17:48:58 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.83 | 2.85 | 0.02 | 0.7% | 6 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 12,957 | 3,306,294 | $ 2.81 | $ 9,296,682 | 3,611,520 | 1.38 - 9.73 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:48:00 | formt | 100 | $ 2.83 | USD |
BioCryst Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 432.91M | 154.06M | $ -101.25M | -0.98 | - | 149.76M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 21.00 | 2.80% |
BioCryst Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/19/2020 | 17:14 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 17:12 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 17:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 17:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:58 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:54 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/18/2020 | 07:11 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BCRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.89 | 3.08 | 2.74 | 2.89 | 2,684,877 | -0.08 | -2.77% |
| 1 Month | 3.00 | 3.68 | 2.71 | 2.99 | 3,511,304 | -0.19 | -6.33% |
| 3 Months | 2.49 | 3.68 | 2.46 | 2.97 | 3,044,614 | 0.32 | 12.85% |
| 6 Months | 2.60 | 3.68 | 1.38 | 2.69 | 2,496,328 | 0.21 | 8.08% |
| 1 Year | 8.97 | 9.73 | 1.38 | 3.48 | 2,053,705 | -6.16 | -68.67% |
| 3 Years | 6.60 | 9.97 | 1.38 | 4.84 | 1,439,221 | -3.79 | -57.42% |
| 5 Years | 10.07 | 16.83 | 1.38 | 5.49 | 1,234,670 | -7.26 | -72.1% |
BioCryst Pharmaceuticals Description
| BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
